Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03004534 · ClinicalTrials.gov registry record · Early Phase 1
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
A Early Phase 1 study of Breast Cancer Female, sponsored by Translational Research in Oncology.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 14
- Study locations
NCT03004534 is a Early Phase 1 study of Breast Cancer Female that has completed, run by Translational Research in Oncology. The registered enrollment target is 36 participants, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (95% lower). The trial reports 14 study locations across 5 states.
The verdict
NCT03004534, a Early Phase 1 study of Breast Cancer Female, has completed, sponsored by Translational Research in Oncology.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of short-term treatment with darolutamide on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast cancer cells) and to evaluate its safety and the way it is tolerated by subjects. The intent is to study these changes in order to have a better understanding of the potential use of darolutamide for women with EBC, know which patients are likely or unlikely to respond to this treatment, and determine how darolutamide may be combined with other anti-cancer drugs.
Conditions Studied
Interventions
- DRUG darolutamide
Study Locations (14)
Quebec
- (CIUSSS) de l'Est-de-l'Île-de-Montréal - l'Hôpital Maisonneuve-Rosemont - Montreal
- Centre Hospitalier de l'Université de Montréal (CHUM) - Montreal
- Jewish General Hospital - Montreal
- McGill University Hospital - Montreal
- Centre Hospitalier Affilie Universitaire De Quebec - Hospital Du Saint-Sacrement - Québec
California
- UCLA - Los Angeles
- Valley Breast Care and Women's Health Center - Los Angeles
- Torrance Memorial Physician Network, Cancer Care Associates - Redondo Beach
- Central Coast Medical Oncology - Santa Maria
Other
- Universitatsklinikum Erlangen - Erlangen
- Interdisziplinares Onkologisches Zentrum - München
- Department of Women's Health - Tübingen
Florida
- UF Health Cancer Center - Orlando Health - Orlando
Alberta
- Cross Cancer Institute - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2019-03-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03004534
The ClinicalTrials.gov registry entry for NCT03004534 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (95% lower). The listed sponsor is Translational Research in Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which darolutamide is the first listed.
NCT03004534 reports 14 study locations spanning 5 distinct geographic areas - top geographies include Quebec, California, Other.
Frequently Asked Questions
What is clinical trial NCT03004534 about?
NCT03004534 is a clinical study titled "A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide". The purpose of this study is to evaluate the effect of short-term treatment with darolutamide on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast cancer cells) and to evaluate its safety and the way it is tolerated by subjects. The intent is to study these cha...
What is the current status of trial NCT03004534?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2017-09-05. Estimated completion is 2019-03-13.
What conditions does trial NCT03004534 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT03004534?
The interventions under investigation include: darolutamide (DRUG).
Who is sponsoring clinical trial NCT03004534?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03004534 being conducted?
This trial has 14 study locations across California, Florida, Alberta, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Streaming Web-based Exercise At Home: A Pilot Study
COMPLETED · Early Phase 1
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.